Study of ESG406 in Adults With Solid Tumors
Recruiting now · Phase 1
Conditions studied: Locally Advanced/Metastatic Solid Tumors
In brief
This study is an open-label, dose-escalation and cohort expansion Phase I study, aiming to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of ESG406, and determine the MTD, RP2D and administration regimens of ESG406. The study includes the dose escalation study in Phase Ia and the cohort expansion study in Phase Ib.
Key facts
- Study ID
- NCT06979674
- Run by
- Shanghai Escugen Biotechnology Co., Ltd
- People needed
- 556
- Starts
- 2025-06-04
- Expected to finish
- 2028-06-01
- Last updated by the study team
- 2025-09-12
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Chongqing University Cancer Hospital — Chongqing, Chongqing Municipality, China (enrolling)
- The First Affiliated Hospital of Xi 'An Jiaotong University — Xi’an, Shanxi, China (enrolling)
- The Second Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.